Interhelical interaction and receptor phosphorylation regulate the activation kinetics of different human β1-adrenoceptor variants.

Andrea Ahles, Fabian Rodewald, Francesca Rochais, Moritz Bünemann, Stefan Engelhardt

Journal: The Journal of biological chemistry 2015;290(3):1760-9

PMID: 25451930

Abstract

G protein-coupled receptors represent the largest class of drug targets, but genetic variation within G protein-coupled receptors leads to variable drug responses and, thereby, compromises their therapeutic application. One of the most intensely studied examples is a hyperfunctional variant of the human β1-adrenoceptor that carries an arginine at position 389 in helix 8 (Arg-389-ADRB1). However, the mechanism underlying the higher efficacy of the Arg-389 variant remained unclear to date. Despite its hyperfunctionality, we found the Arg-389 variant of ADRB1 to be hyperphosphorylated upon continuous stimulation with norepinephrine compared with the Gly-389 variant. Using ADRB1 sensors to monitor activation kinetics by fluorescence resonance energy transfer, Arg-389-ADRB1 exerted faster activation speed and arrestin recruitment than the Gly-389 variant. Both activation speed and arrestin recruitment depended on phosphorylation of the receptor, as shown by knockdown of G protein-coupled receptor kinases and phosphorylation-deficient ADRB1 mutants. Structural modeling of the human β1-adrenoceptor suggested interaction of the side chain of Arg-389 with opposing amino acid residues in helix 1. Site-directed mutagenesis of Lys-85 and Thr-86 in helix 1 revealed that this interaction indeed determined ADRB1 activation kinetics. Taken together, these findings indicate that differences in interhelical interaction regulate the different activation speed and efficacy of ADRB1 variants.

© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Address: From the Institute of Pharmacology and Toxicology, Technische Universität München, 80802 Munich, Germany.; the Rudolf Virchow Center for Experimental Biomedicine, Universität Würzburg, 97080 Würzburg, Germany.; the Institute of Pharmacology and Clinical Pharmacy, Universität Marburg, 35043 Marburg, Germany, and.; From the Institute of Pharmacology and Toxicology, Technische Universität München, 80802 Munich, Germany, the German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, 80802 Munich, Germany [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.